ACVR1 and neoplasm: In conclusion, this study highlights the role of mutant ACVR1 and H3.1K27M in tumor initiation and identifies the BMP pathway, particularly LDN212854, as a promising therapeutic agent for further evaluation in ACVR1 mutant DIPG.